Japan monitors the performance of reimbursed medical devices through mandatory post-market surveillance, requiring manufacturers to report adverse events, conduct post-market studies, and submit periodic safety updates to MHLW and PMDA. This process ensures devices maintain safety, efficacy, and quality while aligning with reimbursement criteria under the NHI system for continued market access.
